PFA is associated with a significantly lower risk for recurrence of atrial arrhythmia compared with antiarrhythmic-drug therapy receipt.
Sri Sri Holistic Hospitals is proud to announce the launch of India's first revolutionary Pulse Field Ablation (PFA) ...
The ACC, AHA, and HRS have released the 2026 advanced training statement on clinical cardiac electrophysiology.
CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress ...
Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE ...
Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST ...
Before adjustment, there were U-shaped relationships between resting heart rate and either any stroke or ischemic stroke, ...
The company initiated its next development program for etripamil, starting a Phase III AFib-RVR trial. “We have initiated our Phase III trial for atrial fibrillation with rapid ventricular rate or ...
With the paid subscription, you also get additional benefits such as cloud storage, blood pressure monitoring, medication ...
Hengrui Pharma (Hengrui) and Braveheart Bio (Braveheart) today announced results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (also known as ...
An RCT is planned in patients with conduction disturbances not covered by current pacing indications, says Josep Rodés-Cabau.
Founding Architect of Canadian Cardiac Electrophysiology and 45-Year Authority on Electrocardiography Joins AIML's Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results